Skip to Content

Jinsong Liu, M.D., MA, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor (Tenure), Section of Gynecologic Pathology, Department of Pathology/Laboratory Medicine, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Member, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1990 Case Western Reserve University, Cleveland, OH, PHD, Biochemistry
1987 Indiana University, Bloomington, IN, MA, Biology
1983 Shanghai Medical University, Shanghai, China, MD, Medicine

Postgraduate Training

7/1999-6/1999 Fellow in Surgical Pathology, New York University Medical Center, New York, NY
4/1994-6/1999 Resident in Pathology, New York University Medical Center, New York, NY
2/1991-10/1993 Post-doctoral Fellow, Howard Hughes Medical Inst.,Bio.Cheminstry& InternalMedicine The UniversityofMichigan Medical Center, Ann Arbor, MI

Honors and Awards

2004-present American's Top Physician, "Guide to America's Top Physician", Consumer's Research Council of America
2001-present Incentive Salary Awards, The University of Texas M. D. Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Haria D, Trinh BQ, Ko SY, Barengo N, Liu J, Naora H. The Homeoprotein DLX4 Stimulates NF-κB Activation and CD44-Mediated Tumor-Mesothelial Cell Interactions in Ovarian Cancer. Am J Pathol. e-Pub 6/8/2015. PMID: 26067154.
2. Chen HH, Chen WC, Liang ZD, Tsai WB, Long Y, Aiba I, Fu S, Broaddus R, Liu J, Feun LG, Savaraj N, Kuo MT. Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opin Ther Targets. e-Pub 5/25/2015. PMID: 26004625.
3. Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 235(1):25-36, 1/2015. e-Pub 11/6/2014. PMCID: PMC4268369.
4. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 7/6/2015. PMID: 26146988.
5. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 17(1):87, 2015. e-Pub 6/25/2015. PMCID: PMC4480452.
6. Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Li Y, Yang Q, Liu J, Wei JJ, Shao C, Liu Z, Kong B. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget 5(21):10816-29, 11/15/2014. PMCID: PMC4279412.
7. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK. Notch3 pathway alterations in ovarian cancer. Cancer Res 74(12):3282-93, 6/15/2014. e-Pub 4/17/2014. PMCID: PMC4058356.
8. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 4/24/2014. e-Pub 4/3/2014. PMCID: PMC4038960.
9. Zhang S, Mercado-Uribe I, Liu J. Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int J Cancer 134(3):508-18, 2/1/2014. e-Pub 7/13/2013. PMID: 23754740.
10. Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 33(1):116-28, 1/2014. e-Pub 3/2013. PMCID: PMC3844126.
11. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 5:3459, 2014. e-Pub 3/12/2014. PMID: 24619206.
12. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun 5:5092, 2014. e-Pub 10/3/2014. PMCID: PMC4185407.
13. Deng Z, Yin B, Li W, Liu J, Yang J, Zheng T, Zhang D, Yu H, Liu X, Ma J. Surface characteristics of and in vitro behavior of osteoblast-like cells on titanium with nanotopography prepared by high-energy shot peening. Int J Nanomedicine 9:5565-73, 2014. e-Pub 11/28/2014. PMCID: PMC4257054.
14. Zhang S, Mercado-Uribe I, Hanash S, Liu J. iTRAQ-based proteomic analysis of polyploid giant cancer cells and budding progeny cells reveals several distinct pathways for ovarian cancer development. PLoS One 8(11):e80120, 2013. e-Pub 11/14/2013. PMCID: PMC3858113.
15. Huang J, Zhang J, Li H, Lu Z, Shan W, Mercado-Uribe I, Liu J. VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am J Transl Res 5(3):336-46, 2013. e-Pub 4/19/2013. PMCID: PMC3633976.

Grant & Contract Support

Title: Tissue Pathology Core, Personalized Enhancement of Primary Ovarian Cancer Chemotherapy
Funding Source: Cancer Prevention and Research Institute of Texas (CPRIT)
Role: Co-Principal Investigator
Principal Investigator: Bast
Duration: 5/1/2011 - 4/30/2016
Title: Multifuctional roles of homeobox gene D LX4 in ovarian cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Honami Naora
Duration: 4/1/2010 - 3/31/2015
Title: Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Fang
Duration: 12/1/2009 - 11/30/2014
Title: Center for Systems Analysis of the Cancer Regulome
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Zhang, Wei
Duration: 9/1/2009 - 8/14/2014
Title: AHRI (DIRAS3) In Autophagy and Dormancy of Ovarian Cancer
Funding Source: NIH/NIC
Role: Co-Investigator
Principal Investigator: Robert Bast
Duration: 7/17/2009 - 6/30/2013
Title: Ras signaling, senescent fibroblasts, and ovarian cancer progression
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2008 - 4/30/2013
Title: Role of Hox Gene in Ovarian Neoplasia
Funding Source: NIH/NIC
Role: Co-Investigator
Principal Investigator: Honami Naora
Duration: 4/1/2004 - 2/28/2015
Title: Role of BRCA1 and telemerase activation in the progession of breast cancer and clinical application
Funding Source: Department of Defense (DOD)
Role: Sponser and Mentor
Principal Investigator: Zhou
Duration: 9/1/2001 - 8/30/2003
Title: Specialized Program in Research Excellence (SPORE) in Ovarian Cancer (PC-C2), Tissue Pathology Core
Funding Source: The University of Texas M.D. Anderson Cancer Center
Role: Co-Principal Investigator
Principal Investigator: Bast, RC
Duration: 9/30/1999 - 8/31/2115
Title: Project 1, Early detection of human ovarian cancer. Specialized Program in Research Excellence (SPORE) in Ovarian Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Bast, Robert C
Duration: 9/30/1999 - 8/31/2010
Title: PI of Project 1: Inflammation in Stromal Fibroblasts and Ovarian Cancer Development; PI of Project 2: Pathology Core, Dissection of Tumor-Stroma Interactions in Ovarian Carcinma
Funding Source: Cancer Prevention and Research Institute of Texas (CPRIT)
Role: Co-Investigator

Last updated: 7/28/2015